摘要 |
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/orwherein the remission of the metabolic disorder, preferably diabetic remission,is achieved and/or maintained. |
申请人 |
BOEHRINGER INGELHEIM VETMEDICA GMBH |
发明人 |
REICHE, DANIA BIRTE;HAAG-DIERGARTEN, SILKE;HENNINGS, LEAH JEANETTE;KLEY, SASKIA;TRAAS, ANNE M. |